title: [Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis].
abstract: This review includes results of experimental and clinical studies of dimethyl fumarate, a new oral drug for pathogenetic treatment of multiple sclerosis (MS). The mechanism of action, data from clinical trials, including MRI-results related to tolerability and safety of the drug are reviewed. The risk management plan for possible adverse events and a place of dimethyl fumarate in the current pathogenetic treatment of MS are discussed.
authors.affiliation: City Clinical Hospital #24, Moscow, Russia; Pirogov Russian National Resaerch Medical University, Moscow, Russia.
authors.forename: E V
authors.initials: EV
authors.lastname: Popova
authors.affiliation: City Clinical Hospital #24, Moscow, Russia; Pirogov Russian National Resaerch Medical University, Moscow, Russia.
authors.forename: A N
authors.initials: AN
authors.lastname: Boyko
authors.affiliation: 'Jonson&amp ,Jonson Ltd', Moscow, Russia.
authors.forename: E V
authors.initials: EV
authors.lastname: Orlova
mesh_terms: D000284:Administration, Oral; D000069462:Dimethyl Fumarate / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D000069462:Dimethyl Fumarate